Quick Answer
MYRIAD GENETICS INC reported Total Revenue of $824.50 million for fiscal year 2025.
MYRIAD GENETICS INC — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $824.50M -1.6% |
$837.60M +11.2% |
$753.20M +11.0% |
$678.40M -1.8% |
$690.60M +8.1% |
$638.60M -25.0% |
| Revenue (ASC 606) | $824.50M -1.6% |
$837.60M +11.2% |
$753.20M +11.0% |
$678.40M -1.8% |
$690.60M +8.1% |
$638.60M -25.0% |
| Net Income | -$365.90M -187.4% |
-$127.30M +51.7% |
-$263.30M -135.1% |
-$112.00M -311.8% |
-$27.20M +86.4% |
-$199.50M -4437.0% |
| Diluted EPS | -$3.95 -180.1% |
-$1.41 +55.7% |
-$3.18 -128.8% |
-$1.39 -297.1% |
-$0.35 +87.0% |
-$2.69 -4583.3% |
| Total Assets | $706.60M -31.2% |
$1.03B -10.4% |
$1.15B -4.4% |
$1.20B -9.2% |
$1.32B -6.0% |
$1.40B -10.1% |
| Cash and Equivalents | $149.60M +46.1% |
$102.40M -22.5% |
$132.10M +132.2% |
$56.90M -77.9% |
$257.40M +57.2% |
$163.70M +75.6% |
| Long-Term Debt | $119.90M +202.8% |
$39.60M +2.9% |
$38.50M | $0.00 | $0.00 -100.0% |
$224.40M -3.9% |
| Stockholders Equity | $368.00M -47.5% |
$701.10M -10.5% |
$783.20M -11.6% |
$885.80M -8.5% |
$967.80M +5.4% |
$918.20M -15.7% |
| R&D Expense | $106.80M -5.8% |
$113.40M +27.8% |
$88.70M +3.9% |
$85.40M +4.3% |
$81.90M +6.1% |
$77.20M -10.1% |
| Operating Income | -$387.20M -213.5% |
-$123.50M +52.0% |
-$257.40M -83.1% |
-$140.60M +26.2% |
-$190.50M +17.8% |
-$231.70M -3148.7% |
| Gross Profit | $576.60M -1.5% |
$585.40M +13.2% |
$517.00M +8.5% |
$476.40M | — | — |
| Shares Outstanding | 93.50M +2.4% |
91.30M +1.6% |
89.90M +10.7% |
81.20M +1.5% |
80.00M +7.1% |
74.70M +1.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $205.70M | -3.6% | -3.5% |
| Revenue (ASC 606) | September 30, 2025 | $205.70M | -3.6% | -3.5% |
| Net Income | September 30, 2025 | -$27.40M | -24.0% | +91.7% |
| Diluted EPS | September 30, 2025 | -$0.29 | -20.8% | +91.9% |
| Total Assets | September 30, 2025 | $728.10M | -32.7% | +7.5% |
| Cash and Equivalents | September 30, 2025 | $145.40M | +45.5% | +95.4% |
| Long-Term Debt | September 30, 2025 | $119.50M | +206.4% | — |
| Stockholders Equity | September 30, 2025 | $372.80M | -49.1% | -3.9% |
| R&D Expense | September 30, 2025 | $28.20M | -1.1% | +10.2% |
| Operating Income | September 30, 2025 | -$23.30M | -16.5% | +92.9% |
| Gross Profit | September 30, 2025 | $143.80M | -4.0% | -5.3% |
| Shares Outstanding | September 30, 2025 | 93.10M | +2.3% | +0.0% |
- MYRIAD GENETICS INC reported Total Revenue of $824.50 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -1.6% in Total Revenue compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Revenue (ASC 606) of $824.50 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -1.6% in Revenue (ASC 606) compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Net Income of -$365.90 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -187.4% in Net Income compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Diluted EPS of $3.95 per share (loss) for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -180.1% in Diluted EPS compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Total Assets of $706.60 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -31.2% in Total Assets compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Cash and Equivalents of $149.60 million for fiscal year 2025.
- MYRIAD GENETICS INC showed an increase of +46.1% in Cash and Equivalents compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Long-Term Debt of $119.90 million for fiscal year 2025.
- MYRIAD GENETICS INC showed an increase of +202.8% in Long-Term Debt compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Stockholders Equity of $368.00 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -47.5% in Stockholders Equity compared to the prior fiscal year.
- MYRIAD GENETICS INC reported R&D Expense of $106.80 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -5.8% in R&D Expense compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Operating Income of -$387.20 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -213.5% in Operating Income compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Gross Profit of $576.60 million for fiscal year 2025.
- MYRIAD GENETICS INC showed a decrease of -1.5% in Gross Profit compared to the prior fiscal year.
- MYRIAD GENETICS INC reported Shares Outstanding of 93.50 million shares for fiscal year 2025.
- MYRIAD GENETICS INC showed an increase of +2.4% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: